To provide you with a better experience, our website uses cookies. To continue browsing, you please accept our cookies policy.

J'accepte

Cookies informations

Our site uses tools, such as cookies, to analyse and improve your experience. You can unsubscribe from these follow-ups:

Statistics

Nous utilisons des outils, tels que Google Analytics, pour suivre le trafic Web et vérifier l'efficacité de notre site.

Essential

Cookies requis pour les services essentiels et les fonctionnalités telles que les formulaires de connexion, l'intégration du panier et le contrôle d'accès. Sans eux, notre site Web ne peut pas fonctionner correctement et nous ne pouvons fournir aucun service. La désactivation n'est pas disponible.

These parameters will be stored for 24 hours

Media Room

Our last news

Events

09-02-2021
IRE submits its request for a single permit for the construction of a 100% Walloon cyclotron

In 2020, IRE signed a contract with IBA to build a cyclotron on its site in Fleurus. This state-of-the-art equipment will enable the IRE to produce Germanium-68 locally, a key raw material to enable the institute to contribute even more to the fight against cancer. The IRE is pursuing the progress of this project by submitting today an application for a single permit (urban planning and environmental permit).

07-01-2021
IRE ELiT and ROTOP Pharmaka enter into a distribution partnership in Germany for Germanium-68/Gallium-68 generator

IRE ELiT and ROTOP Pharmaka, two innovative radiopharmaceuticals companies focused on diagnostics and therapeutics announce today they have entered into an exclusive commercial agreement for the distribution of Galli Ad (the Ge-68/Ga-68 generator from IRE ELiT) in Germany.

15-09-2020
IBA selected to equip IRE’s new radioisotope production unit dedicated to cancer diagnosis

The Institute of Radioelements (IRE) has commissioned the Louvain-la-Neuve-based company IBA to install a particle accelerator for the production of radioisotopes for the diagnosis of numerous cancer types such as neuroendocrine tumors and prostate cancer.

30-04-2020
IRE supplies a first commercial batch of LEU-based Mo-99

The Institute for radioelements (IRE), one of the leaders in the production of Molybdenum-99 (Mo-99), the most widely used radio-isotope in nuclear medicine for diagnosis, announced today that the company produced its first commercial Mo-99 Low Enriched Uranium (LEU) batch for the US market.

09-01-2020
IRE ELiT and Telix Pharmaceuticals enter French Distribution Agreement for Prostate Cancer Imaging

We are proud to announce today that we have signed a distribution agreement with Advanced Nuclear Medicine Ingredient S.A., a subsidiary of Telix Pharmaceuticlas Limited, for the distribution of the metastatic prostate cancer imaging product TLX591-CDx (68Ga-PSMA-11), a radiopharmaceutical cold kit complementary of its GalliAd 68Ge/68Ga new generation generator, specifically designed for cold kits preparation.